Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA)
CUSIP: 152309100
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Ordinary shares, nominal value 0.002 GBP per share
- Shares outstanding
- 145,993,531
- Total 13F shares
- 86,506,981
- Share change
- +12,111,714
- Total reported value
- $781,158,600
- Put/Call ratio
- 25%
- Price per share
- $9.03
- Number of holders
- 79
- Value change
- +$108,671,569
- Number of buys
- 43
- Number of sells
- 25
Quarterly Holders Quick Answers
What is CUSIP 152309100?
CUSIP 152309100 identifies CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 152309100:
Top shareholders of CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd |
13F
3/4/5
|
Company · 10%+ Owner |
14%
|
19,963,157
|
$225,583,674 | — | 31 Mar 2024 | |
| GENERAL ATLANTIC, L.P. |
13F
|
Individual |
6.6%
|
9,681,818
|
$109,404,543 | — | 31 Mar 2024 | |
| EcoR1 Capital, LLC |
13F
|
Company |
3.8%
|
5,618,779
|
$63,492,203 | — | 31 Mar 2024 | |
| Vida Ventures Advisors, LLC |
13F
|
Company |
2.7%
|
3,931,818
|
$44,429,544 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
2.1%
|
3,083,307
|
$34,841,369 | — | 31 Mar 2024 | |
| First Light Asset Management, LLC |
13F
|
Company |
2.1%
|
3,002,045
|
$33,923,109 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2%
|
2,958,079
|
$33,427,000 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
1.9%
|
2,787,194
|
$31,495,292 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.5%
|
2,257,718
|
$25,512,213 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.5%
|
2,250,000
|
$25,425,000 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.5%
|
2,137,365
|
$24,152,225 | — | 31 Mar 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1.4%
|
2,060,100
|
$23,279,130 | — | 31 Mar 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.4%
|
2,040,816
|
$23,061,221 | — | 31 Mar 2024 | |
| Artal Group S.A. |
13F
|
Company |
0.97%
|
1,412,500
|
$15,961,250 | — | 31 Mar 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.85%
|
1,245,000
|
$14,068,500 | — | 31 Mar 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.79%
|
1,156,723
|
$13,070,970 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.76%
|
1,104,014
|
$12,475,358 | — | 31 Mar 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.63%
|
923,120
|
$10,431,267 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.57%
|
830,546
|
$9,385,170 | — | 31 Mar 2024 | |
| David J. Grainger |
3/4/5
|
Chief Innovation Officer |
—
class O/S missing
|
990,290
|
$7,882,708 | — | 31 Dec 2023 | |
| Tanager Wealth Management LLP |
13F
|
Company |
0.48%
|
696,096
|
$7,865,885 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.38%
|
561,600
|
$6,346,080 | — | 31 Mar 2024 | |
| Antoine Yver |
3/4/5
|
EVP & Chairman of Development |
—
class O/S missing
|
783,066
|
$6,233,205 | — | 01 Jun 2023 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
0.33%
|
485,174
|
$5,482,466 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.26%
|
382,462
|
$4,321,821 | — | 31 Mar 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.26%
|
379,314
|
$4,286,000 | — | 31 Mar 2024 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.25%
|
371,000
|
$4,192,300 | — | 31 Mar 2024 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.22%
|
314,674
|
$3,555,816 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.2%
|
287,393
|
$3,247,541 | — | 31 Mar 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
0.19%
|
274,900
|
$3,106,370 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.17%
|
254,446
|
$2,875,240 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.16%
|
231,565
|
$2,616,685 | — | 31 Mar 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.16%
|
228,644
|
$2,583,677 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.15%
|
218,800
|
$2,472,000 | — | 31 Mar 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.14%
|
206,856
|
$2,337,473 | — | 31 Mar 2024 | |
| Francesco de Rubertis |
3/4/5
|
Director |
—
class O/S missing
|
281,162
|
$2,238,050 | — | 21 Mar 2022 | |
| Thomas Templeman |
3/4/5
|
Chief Technology Officer |
—
class O/S missing
|
188,244
|
$1,498,422 | — | 31 Mar 2023 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.09%
|
125,157
|
$1,414,274 | — | 31 Mar 2024 | |
| Javad Shahidi |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
158,932
|
$1,265,099 | — | 30 Sep 2022 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.07%
|
108,048
|
$1,220,942 | — | 31 Mar 2024 | |
| INDEX VENTURES LIFE VI (JERSEY) L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
149,421
|
$1,189,391 | — | 27 May 2021 | |
| Trexquant Investment LP |
13F
|
Company |
0.07%
|
96,531
|
$1,090,800 | — | 31 Mar 2024 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.06%
|
90,240
|
$1,019,712 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.05%
|
78,781
|
$890,225 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
76,984
|
$869,919 | — | 31 Mar 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.05%
|
72,609
|
$820,482 | — | 31 Mar 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
69,109
|
$780,932 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.04%
|
55,027
|
$621,805 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.03%
|
46,968
|
$530,738 | — | 31 Mar 2024 | |
| Harris Rotman |
3/4/5
|
SVP Regulatory Affairs |
—
mixed-class rows
|
137,625
mixed-class rows
|
$507,432 | — | 01 Feb 2024 |
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) as of Q2 2024
As of 30 Jun 2024,
Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
86,506,981 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, GENERAL ATLANTIC, L.P., EcoR1 Capital, LLC, First Light Asset Management, LLC, PERCEPTIVE ADVISORS LLC, Vida Ventures Advisors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, ADAGE CAPITAL PARTNERS GP, L.L.C., TCG Crossover Management, LLC, and FMR LLC.
This page lists
79
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
69
Q2 2024 holders
79
Holder diff
10
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.